Astrazeneca acquires biotech firm for up to USD 1.3bn

Pharmaceutical giant Astrazeneca is acquiring Teneotwo to get its hands on TNB-486, a potential lymph node cancer candidate.


Astrazeneca has entered an agreement to acquire biotech firm Teneotwo for up to USD 1.3bn, Bloomberg News reports.

The British-Swedish firm is paying USD 100m upfront, while the rest will be in the form of milestone payments connected to development and commercial targets.

The aim of the acquisition is for Astrazeneca to get its hands on an experimental lymph node cancer treatment. The candidate, called TNB-486, is in the early stages of clinical testing, Astrazeneca reports.

Astrazeneca’s share price increased by 3% on Tuesday.

Overview: Pharma giants and Bavarian Nordic fight over billion-dollar vaccine market

Moderna on booster race: May the best data win

Genmab to submit cancer candidate epcoritamab to the FDA before year-end

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs